| Authors: |
Cárdenas V; Janssen Research & Development LLC, Spring House, PA, United States. Electronic address: cardenasv@yahoo.com., Le Gars M; Janssen Vaccines & Prevention, Leiden, the Netherlands. Electronic address: Mathieu.legars1@gmail.com., Truyers C; Janssen Research & Development, Beerse Belgium. Electronic address: ctruyers@its.jnj.com., Ruiz-Guiñazú J; Janssen Research & Development, Beerse Belgium. Electronic address: JRuizGui@its.jnj.com., Struyf F; Janssen Research & Development, Beerse Belgium. Electronic address: fstruyf@gmail.com., Colfer A; Janssen Research & Development LLC, Spring House, PA, United States. Electronic address: acolfer@its.jnj.com., Bonten M; Julius Center for Health Services and Primary Care, UMC Utrecht, Utrecht University and European Clinical Alliance on Infectious Diseases, Utrecht, the Netherlands. Electronic address: m.j.m.bonten@umcutrecht.nl., Borobia A; Clinical Pharmacology Department, La Paz University Hospital. School of Medicine, Universidad Autónoma de Madrid, IdiPAZ. CIBERINFECT, Spain. Electronic address: alberto.borobia@salud.madrid.org., Reisinger EC; Rostock University Medical Center, Dept. of Infectious Diseases and Tropical Medicine, Rostock, Germany. Electronic address: emil.reisinger@uni-rostock.de., Kamerling IMC; Centre for Human Drug Research, Zernikedreef 8, 2333 CL Leiden, the Netherlands. Electronic address: idvisser@chdr.nl., Douoguih M; Janssen Vaccines & Prevention, Leiden, the Netherlands. Electronic address: macaya.douoguih@merck.com., Sadoff J; Janssen Vaccines & Prevention, Leiden, the Netherlands. Electronic address: Jerry@Centivax.com. |
